The myeloid-binding peptide adenoviral vector enables multi-organ vascular endothelial gene targeting

Laboratory Investigation

Volumn 94, Issue 8, 2014, Pages 881-892

  Lu, Zhi Hong ^a   Kaliberov, Sergey ^a   Zhang, Jingzhu ^a   Muz, Barbara ^a   Azab, Abdel K ^a   Sohn, Rebecca E ^a   Kaliberova, Lyudmila ^a   Du, Yingqiu ^a   Curiel, David T ^a   Arbeit, Jeffrey M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CYTOMEGALOVIRUS VECTOR; HEPTAPEPTIDE; MYELOID BINDING PEPTIDE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CYTOMEGALOVIRUS; ENHANCER REGION; EX VIVO STUDY; GENE; GENE EXPRESSION; HUMAN; HUMAN ADENOVIRUS 5; HUMAN CELL; IMMUNOFLUORESCENCE; LIVER CELL; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; ROBO4 GENE; SOMATIC MUTATION; TRANSGENE; VASCULAR ENDOTHELIUM; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; CYTOMEGALOVIRUS; ENDOTHELIUM, VASCULAR; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HEPATOCYTES; HUMANS; INJECTIONS, INTRAVENOUS; MICE; MICE, INBRED C57BL; MYELOID CELLS; PEPTIDES; PROMOTER REGIONS, GENETIC; RECEPTORS, CELL SURFACE; RECOMBINANT FUSION PROTEINS; VIRAL PROTEINS; VIRAL TROPISM; VIRION;

EID: 84905181548     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2014.78     Document Type: Article

References (70)

1. Alberti MO, Deshane JS, Chaplin DD, et al. A myeloid cell-binding adenovirus efficiently targets gene transfer to the lung and escapes liver tropism. Gene Therapy 2013;20:733-741.
2. Dong Z, Nor JE. Transcriptional targeting of tumor endothelial cells for gene therapy. Adv Drug Deliv Rev 2009;61:542-553.
3. Nicol CG, Denby L, Lopez-Franco O, et al. Use of in vivo phage display to engineer novel adenoviruses for targeted delivery to the cardiac vasculature. FEBS Lett 2009;583:2100-2107.
4. Bradshaw AC, Baker AH. Gene therapy for cardiovascular disease: perspectives and potential. Vasc Pharmacol 2013;58:174-181.
5. Muro S, Koval M, Muzykantov V. Endothelial endocytic pathways: gates for vascular drug delivery. Curr Vasc Pharmacol 2004;2:281-299.
6. Glasgow JN, Everts M, Curiel DT. Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther 2006;13: 830-844.
7. Haisma HJ, Kamps GK, Bouma A, et al. Selective targeting of adenovirus to alphavbeta3 integrins, VEGFR2 and Tie2 endothelial receptors by angio-adenobodies. Int J Pharmaceut 2010;391:155-161.
8. Duffy MR, Parker AL, Bradshaw AC, et al. Manipulation of adenovirus interactions with host factors for gene therapy applications. Nanomedicine (Lond) 2012;7:271-288.
9. Beatty MS, Curiel DT. Chapter two-adenovirus strategies for tissue-specific targeting. Adv Cancer Res 2012;115:39-67.
10. Kaliberov SA, Kaliberova LN, Hong LuZ, et al. Retargeting of gene expression using endothelium specific hexon modified adenoviral vector. Virology 2013;447:312-325.
11. Magnenat L, Schwimmer LJ, Barbas 3rd CF. Drug-inducible and simultaneous regulation of endogenous genes by single-chain nuclear receptor-based zinc-finger transcription factor gene switches. Gene Therapy 2008;15:1223-1232.
12. Bochman ML, Paeschke K, Zakian VA. DNA secondary structures: stability and function of G-quadruplex structures. Nat Rev Genet 2012;13:770-780.
13. van Rooij E. The art of microRNA research. Circ Res 2011;108:219-234.
14. Baker AH, Kritz A, Work LM, et al. Cell-selective viral gene delivery vectors for the vasculature. Exp Physiol 2005;90:27-31.
15. Lindemann D, Schnittler H. Genetic manipulation of endothelial cells by viral vectors. Thromb Haemost 2009;102:1135-1143.
16. Franses JW, Edelman ER. The evolution of endothelial regulatory paradigms in cancer biology and vascular repair. Cancer Res 2011;71: 7339-7344.
17. Alberti MO, Roth JC, Ismail M, et al. Derivation of a myeloid cell-binding adenovirus for gene therapy of inflammation. PLoS One 2012;7:e37812.
18. Belousova N, Korokhov N, Krendelshchikova V, et al. Genetically targeted adenovirus vector directed to CD40-expressing cells. J Virol 2003;77:11367-11377.
19. He TC, Zhou S, da Costa LT, et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998;95: 2509-2514.
20. Short JJ, Rivera AA, Wu H, et al. Substitution of adenovirus serotype 3 hexon onto a serotype 5 oncolytic adenovirus reduces factor X binding, decreases liver tropism, and improves antitumor efficacy. Mol Cancer Ther 2010;9:2536-2544.
21. van Rooijen N, Hendrikx E. Liposomes for specific depletion of macrophages from organs and tissues. Methods Mol Biol 2010;605: 189-203.
22. Waddington SN, McVey JH, Bhella D, et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008;132:397-409.
23. Lu ZH, Kaliberov S, Sohn RE, et al. Transcriptional targeting of primary and metastatic tumor neovasculature by an adenoviral type 5 roundabout4 vector in mice. PLoS One 2013;8:e83933.
24. Xu Z, Qiu Q, Tian J, et al. Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nat Med 2013;19:452-457.
25. Wolff G, Worgall S, van Rooijen N, et al. Crystal RG. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J Virol 1997;71: 624-629.
26. Bradshaw AC, Coughlan L, Miller AM, et al. Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses. J Control Release 2012;164:394-402.
27. Aird WC. Endothelial Biomedicine, Cambridge, UK; New York, NY, USA, 2007.
28. Shinozaki K, Suominen E, Carrick F, et al. Efficient infection of tumor endothelial cells by a capsid-modified adenovirus. Gene Therapy 2006;13:52-59.
29. Preuss MA, Glasgow JN, Everts M, et al. Enhanced gene delivery to human primary endothelial cells using tropism-modified adenovirus vectors. Open Gene Ther J 2008;1:7-11.
30. White KM, Alba R, Parker AL, et al. Assessment of a novel, capsid-modified adenovirus with an improved vascular gene transfer profile. J Cardiothorac Surg 2013;8:183.
31. Reynolds PN, Zinn KR, Gavrilyuk VD, et al. A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. Mol Ther 2000;2:562-578.
32. Nettelbeck DM, Miller DW, Jerome V, et al. Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). Mol Ther 2001;3:882-891.
33. Bachtarzi H, Stevenson M, Subr V, et al. E-selectin is a viable route of infection for polymer-coated adenovirus retargeting in TNF-alpha-activated human umbilical vein endothelial cells. J Drug Target 2011;19:690-700.
34. Nicklin SA, Von Seggern DJ, Work LM, et al. Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus. Mol Ther 2001;4: 534-542.
35. Song W, Sun Q, Dong Z, et al. Antiangiogenic gene therapy: disruption of neovascular networks mediated by inducible caspase-9 delivered with a transcriptionally targeted adenoviral vector. Gene Therapy 2005;12:320-329.
36. Greenberger S, Shaish A, Varda-Bloom N, et al. Transcription-controlled gene therapy against tumor angiogenesis. J Clin Invest 2004;113:1017-1024.
37. Reynolds PN, Nicklin SA, Kaliberova L, et al. Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol 2001;19:838-842.
38. Tal R, Shaish A, Rofe K, et al. Endothelial-targeted gene transfer of hypoxia-inducible factor-1alpha augments ischemic neovasculariza-tion following systemic administration. Mol Ther 2008;16:1927-1936.
39. Zaiss AK, Machado HB, Herschman HR. The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem 2009; 108:778-790.
40. Cole C, Qiao J, Kottke T, et al. Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nat Med 2005;11:1073-1081.
41. Roth JC, Curiel DT, Pereboeva L. Cell vehicle targeting strategies. Gene Therapy 2008;15:716-729.
42. Mueller C, Flotte TR. Gene-based therapy for alpha-1 antitrypsin deficiency. COPD 2013;10(Suppl 1):44-49.
43. Flotte TR, Mueller C. Gene therapy for alpha-1 antitrypsin deficiency. Hum Mol Genet 2011;20:R87-R92.
44. Mueller C, Tang Q, Gruntman A, et al. Sustained miRNA-mediated knockdown of mutant AAT with simultaneous augmentation of wild-type AAT has minimal effect on global liver miRNA profiles. Mol Ther 2012;20:590-600.
45. Li C, Xiao P, Gray SJ, et al. Combination therapy utilizing shRNA knockdown and an optimized resistant transgene for rescue of diseases caused by misfolded proteins. Proc Natl Acad Sci USA 2011;108:14258-14263.
46. Oakland M, Sinn PL, McCray Jr. PB. Advances in cell and gene-based therapies for cystic fibrosis lung disease. Mol Ther 2012;20:1108-1115.
47. Kelly E, Greene CM, McElvaney NG. Targeting neutrophil elastase in cystic fibrosis. Expert Opin Ther Targets 2008;12:145-157.
48. Tang T, Hammond HK. Gene transfer for congestive heart failure: update 2013. Transl Res 2013;161:313-320.
49. van Berlo JH, Maillet M, Molkentin JD. Signaling effectors underlying pathologic growth and remodeling of the heart. J Clin Invest 2013; 123:37-45.
50. Kaminsky SM, Rosengart TK, Rosenberg J, et al. Gene therapy to stimulate angiogenesis to treat diffuse coronary artery disease. Hum Gene Ther 2013;24:948-963.
51. Hedman M, Hartikainen J, Syvanne M, et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003;107: 2677-2683.
52. Hedman M, Muona K, Hedman A, et al. Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer. Gene Therapy 2009;16:629-634.
53. Rosengart TK, Lee LY, Patel SR, et al. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg 1999;230:466-470, discussion 470-472.
54. Rosengart TK, Bishawi MM, Halbreiner MS, et al. Long-term follow-up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease. Hum Gene Ther 2013;24:203-208.
55. Stewart DJ, Hilton JD, Arnold JM, et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Therapy 2006;13:1503-1511.
56. Henry TD, Grines CL, Watkins MW, et al. Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol 2007;50:1038-1046.
57. Kastrup J, Jorgensen E, Fuchs S, et al. A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial. EuroIntervention 2011;6:813-818.
58. Oladipupo SS, Hu S, Santeford AC, et al. Conditional HIF-1 induction produces multistage neovascularization with stage-specific sensitivity to VEGFR inhibitors and myeloid cell independence. Blood 2011;117:4142-4153.
59. Elson DA, Thurston G, Huang LE, et al. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. Genes Dev 2001;15:2520-2532.
60. Kamdar F, Jameel MN, Score P, et al. Cellular therapy promotes endogenous stem cell repair. Can J Physiol Pharmacol 2012;90: 1335-1344.
61. Ou DB, Zeng D, Jin Y, et al. The long-term differentiation of embryonic stem cells into cardiomyocytes: an indirect co-culture model. PLoS One 2013;8:e55233.
62. Coune PG, Schneider BL, Aebischer P. Parkinson's disease: gene therapies. Cold Spring Harb Perspect Med 2012;2:a009431.
63. Ramaswamy S, Kordower JH. Gene therapy for Huntington's disease. Neurobiol Dis 2012;48:243-254.
64. Assi H, Candolfi M, Baker G, et al. Gene therapy for brain tumors: basic developments and clinical implementation. Neurosci Lett 2012; 527:71-77.
65. Patel P, Kriz J, Gravel M, et al. Adeno-associated virus-mediated delivery of a recombinant single-chain antibody against misfolded superoxide dismutase for treatment of amyotrophic lateral sclerosis. Mol Ther 2014;22:498-510.
66. Yanamandra K, Kfoury N, Jiang H, et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 2013;80:402-414.
67. Tobias A, Ahmed A, Moon KS, et al. The art of gene therapy for glioma: a review of the challenging road to the bedside. J Neurol Neurosurg Psychiatry 2013;84:213-222.
68. Gilbertson RJ, Rich JN. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer 2007;7:733-736.
69. Galan-Moya EM, Le Guelte A, Lima Fernandes E, et al. Secreted factors from brain endothelial cells maintain glioblastoma stem-like cell expansion through the mTOR pathway. EMBO Rep 2011;12: 470-476.
70. Zhu TS, Costello MA, Talsma CE, et al. Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells. Cancer Res 2011;71: 6061-6072.